iA Global Asset Management Inc. Has $3.22 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

iA Global Asset Management Inc. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 44.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,098 shares of the medical device company's stock after selling 38,702 shares during the period. iA Global Asset Management Inc.'s holdings in DexCom were worth $3,224,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the 2nd quarter worth $25,000. Sachetta LLC grew its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after acquiring an additional 171 shares in the last quarter. DT Investment Partners LLC grew its holdings in DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after acquiring an additional 315 shares in the last quarter. Riverview Trust Co grew its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after acquiring an additional 232 shares in the last quarter. Finally, ORG Partners LLC grew its holdings in DexCom by 1,992.0% during the 2nd quarter. ORG Partners LLC now owns 523 shares of the medical device company's stock worth $59,000 after acquiring an additional 498 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Down 1.5 %

DXCM stock traded down $1.20 during trading hours on Friday, hitting $77.72. The company's stock had a trading volume of 2,644,207 shares, compared to its average volume of 3,793,395. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $30.36 billion, a PE ratio of 46.54, a price-to-earnings-growth ratio of 2.48 and a beta of 1.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a 50 day moving average price of $72.55 and a two-hundred day moving average price of $85.74.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company's stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the business's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock valued at $399,319 over the last ninety days. Corporate insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DXCM shares. Sanford C. Bernstein lifted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. StockNews.com lowered shares of DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. Stifel Nicolaus lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a report on Friday, August 23rd. Royal Bank of Canada decreased their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Finally, Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and a consensus target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.